Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) Short Interest Update

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 135,284 shares, a growth of 190.9% from the July 15th total of 46,508 shares. Based on an average daily volume of 95,778 shares, the days-to-cover ratio is currently 1.4 days.

Drugs Made In America Acquisition II Price Performance

Shares of DMII stock traded down $0.01 during trading hours on Friday, reaching $10.12. The company had a trading volume of 5,125 shares, compared to its average volume of 114,100. Drugs Made In America Acquisition II has a 12-month low of $9.86 and a 12-month high of $10.20. The stock has a fifty day moving average of $10.10 and a 200-day moving average of $10.03.

Analyst Ratings Changes

Several research analysts recently commented on DMII shares. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Drugs Made In America Acquisition II

Several large investors have recently added to or reduced their stakes in the stock. Magnetar Financial LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth $26,730,000. Glazer Capital LLC purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at about $23,264,000. First Trust Capital Management L.P. purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at about $20,474,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Drugs Made In America Acquisition II during the first quarter worth about $19,960,000. Finally, Hudson Bay Capital Management LP purchased a new position in Drugs Made In America Acquisition II during the fourth quarter worth about $19,493,000.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.